{"id":1034412,"date":"2026-08-31T06:03:38","date_gmt":"2026-08-31T06:03:38","guid":{"rendered":"https:\/\/www.europesays.com\/us\/1034412\/"},"modified":"2026-08-31T06:03:38","modified_gmt":"2026-08-31T06:03:38","slug":"arthritis-drug-restores-100-of-hair-on-some-patients-with-severe-alopecia-in-global-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/1034412\/","title":{"rendered":"Arthritis drug restores 100% of hair on some patients with severe alopecia in global trial"},"content":{"rendered":"<p>For many, losing hair isn\u2019t just a cosmetic worry \u2013 it is a deeply personal struggle that can chip away at confidence, social life and <a target=\"_self\" class=\"e1yy41x40 ef9u0v01 css-1ankfgb ecgc78b0\" href=\"https:\/\/www.scmp.com\/topics\/mental-health?module=inline&amp;pgtype=article\" title=\"\" data-qa=\"BaseLink-renderAnchor-StyledAnchor\" rel=\"nofollow noopener\">mental health<\/a>. Now, a surprising candidate is offering new hope: a pill originally designed to treat arthritis.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">The condition is called alopecia areata. It is an autoimmune disease where the body\u2019s own immune system mistakenly attacks hair follicles, causing unpredictable hair loss. Sometimes it is just a few patches but in severe cases, the entire scalp, eyebrows and even body hair can vanish. Until now, there has been no reliably effective treatment.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">Enter upadacitinib. This once-daily oral medication was previously approved to tame inflammation in various forms of arthritis. But scientists suspected it might also help with alopecia areata by calming the same kind of immune overreaction that destroys hair follicles.<\/p>\n<p>To test this, researchers at <a target=\"_self\" class=\"e1yy41x40 ef9u0v01 css-1ankfgb ecgc78b0\" href=\"https:\/\/www.scmp.com\/news\/us\/diplomacy\/article\/3364485\/harvard-mit-among-30-us-universities-ordered-audit-china-research-ties?module=inline&amp;pgtype=article\" title=\"\" data-qa=\"BaseLink-renderAnchor-StyledAnchor\" rel=\"nofollow noopener\">Harvard University<\/a> ran two large, international clinical trials across hospitals in North America, Europe and China. They recruited people with severe alopecia areata.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">On average, the volunteers had lost about 84 per cent of their scalp hair. Some had not seen any regrowth for at least six months.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">Participants were randomly assigned to take either a 15mg dose, a 30mg dose, or a placebo pill every day. The results, published in JAMA Dermatology on August 12, were striking.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">Within just 24 weeks, roughly half of those taking upadacitinib \u2013 both doses combined \u2013 saw at least 80 per cent of their scalp hair grow back.<\/p>\n","protected":false},"excerpt":{"rendered":"For many, losing hair isn\u2019t just a cosmetic worry \u2013 it is a deeply personal struggle that can&hellip;\n","protected":false},"author":3,"featured_media":1034413,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[11],"tags":[4402,413938,413941,16133,165580,74,440,8832,14232,210,413939,236619,587,67,132,413940,68],"class_list":["post-1034412","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-aa","tag-alopecia-areata","tag-arash-mostaghimi","tag-arthritis","tag-brigham-and-womens-hospital","tag-china","tag-europe","tag-harvard-medical-school","tag-harvard-university","tag-health","tag-jama-dermatology","tag-medical-news-today","tag-north-america","tag-united-states","tag-unitedstates","tag-upadacitinib","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/117188611483672377","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/1034412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=1034412"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/1034412\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/1034413"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=1034412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=1034412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=1034412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}